Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to 3 years in a diverse population of adults with overweight or obesity but not ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and prediabetes had a mean weight regain of 3.7% at 176 weeks after reaching their nadir ...

Lilly Sues Four Compounders Over Copies of Weight-Loss Drugs (Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...